Literature DB >> 14871421

Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease.

B Payson Oberg1, Elizabeth McMenamin, F Lee Lucas, Ellen McMonagle, Jason Morrow, T Alp Ikizler, Jonathan Himmelfarb.   

Abstract

BACKGROUND: The prevalence of increased oxidative stress and acute-phase inflammation in patients with chronic kidney disease (CKD) has not been thoroughly investigated.
METHODS: Biomarkers of oxidative stress and acute-phase inflammation were measured in a cohort of 60 patients with stage 3-5 CKD compared to a healthy subject cohort. Levels of oxidative stress and inflammation were also compared to estimated glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula.
RESULTS: All biomarkers of oxidative stress (plasma protein carbonyl group content, plasma free F2-isoprostane content, plasma protein reduced thiol content) and all markers of inflammation [C-reactive protein (CRP), interleukin-6 (IL-6)] differed significantly between CKD patients and healthy subjects. There was no significant relationship between estimated GFR and any oxidative stress or inflammation biomarker. CRP levels were higher in patients with known coronary vascular disease (CVD) and in patients not taking angiotensin II inhibitors. Plasma IL-6 levels were significantly higher in patients with known coronary vascular disease and lower in patients taking statins. Biomarkers of oxidative stress were significantly higher in patients with diabetes and hypercholesterolemia.
CONCLUSION: There is evidence of increased oxidative stress and acute-phase inflammation in patients with stage 3-5 chronic kidney disease compared to healthy subjects that does not closely correlate with estimates of GFR. Among CKD patients, inflammatory biomarkers correlate with known CVD and inversely correlate with the use of angiotensin II inhibitors and statins. A further increase in oxidative stress was noted in diabetic and hypercholesterolemic patients. Inflammation and oxidative stress may contribute to cardiovascular risk in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871421     DOI: 10.1111/j.1523-1755.2004.00465.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  243 in total

1.  Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway.

Authors:  Wei Cao; Jie Xu; Zhan Mei Zhou; Guo Bao Wang; Fan Fan Hou; Jing Nie
Journal:  Antioxid Redox Signal       Date:  2012-07-30       Impact factor: 8.401

2.  Oxidative stress contributes to muscle atrophy in chronic kidney disease patients.

Authors:  Kassia S Beetham; Erin J Howden; David M Small; David R Briskey; Megan Rossi; Nicole Isbel; Jeff S Coombes
Journal:  Redox Rep       Date:  2014-11-13       Impact factor: 4.412

3.  Advanced oxidation protein products promote NADPH oxidase-dependent β-cell destruction and dysfunction through the Bcl-2/Bax apoptotic pathway.

Authors:  Min Liang; Aiqing Li; Aiju Lou; Xifang Zhang; Youyuan Chen; Lei Yang; Yumin Li; Shenglin Yang; Fan Fan Hou
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

4.  Association between age-related decline of kidney function and plasma malondialdehyde.

Authors:  Guolin Li; Yaqin Chen; Hui Hu; Li Liu; Xiaofei Hu; Jun Wang; Wang Shi; Dazhong Yin
Journal:  Rejuvenation Res       Date:  2012-04-24       Impact factor: 4.663

5.  Relation of blood cadmium, lead, and mercury levels to biomarkers of lipid peroxidation in premenopausal women.

Authors:  Anna Z Pollack; Enrique F Schisterman; Lynn R Goldman; Sunni L Mumford; Neil J Perkins; Michael S Bloom; Carole B Rudra; Richard W Browne; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2012-02-02       Impact factor: 4.897

6.  Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents.

Authors:  Takahide Arai; Akio Kawamura; Yumiko Matsubara; Kenji Yokoyama; Yasuo Ikeda; Keiichi Fukuda; Mitsuru Murata
Journal:  Heart Vessels       Date:  2011-08-12       Impact factor: 2.037

7.  Modulation of angiotensin II-induced inflammatory cytokines by the Epac1-Rap1A-NHE3 pathway: implications in renal tubular pathobiology.

Authors:  Ping Xie; Darukeshwara Joladarashi; Pradeep Dudeja; Lin Sun; Yashpal S Kanwar
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-19

8.  Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease.

Authors:  Wanwarat Ananthapanyasut; Sirikarn Napan; Earl H Rudolph; Tasma Harindhanavudhi; Husam Ayash; Kelly E Guglielmi; Edgar V Lerma
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-10       Impact factor: 8.237

9.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

10.  The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.

Authors:  Jennifer C Schroeder; Brett C Dinatale; Iain A Murray; Colin A Flaveny; Qiang Liu; Elizabeth M Laurenzana; Jyh Ming Lin; Stephen C Strom; Curtis J Omiecinski; Shantu Amin; Gary H Perdew
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.